Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Pharmaxis' Aridol Gains First Asian Approval
February 2nd, 2008
Pharmaxis ( NASDAQ: PXSL) announced the Korean regulatory agency has granted marketing approval for its asthma management product, Aridol. "This is the first Asian approval of Aridol," said Pharmaxis Chief Executive Officer Dr Alan Robertson. "Korea is an important base from which to launch and grow Aridol in Asia. There are an estimated 2.5 million asthma sufferers and yet only 160,000 bronchial challenge tests are performed annually to assist with asthma diagnosis and management. The existing broad acceptance of lung function challenge tests presents a firm opportunity for marketing Aridol." Approval by the Korean regulatory agency was based on the...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-02-02)
|
